ClinicalTrials.gg
RecruitingNCT05366933Updated Nov 12, 2026

B-Complex: A Nutraceutical SANS Countermeasure

A Phase 1 interventional study of Vitamin B-Complex Supplement in Optic Disc Edema and Endothelial Dysfunction, sponsored by National Aeronautics and Space Administration (NASA). Recruiting at 1 site in United States. Open to participants aged 20 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Aeronautics and Space Administration (NASA) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Papilledema with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Papilledema · United States.

Started
2022
the only one that year
Phase 1
3 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
National Aeronautics and Space Administration (NASA)

Among the 11 studies in Papilledema with a site in United States, this one is the only one that started in 2022, is one of 3 in phase 1, and was the 10th registered.

Papilledema

29 studies on the registry are indexed under Papilledema; 7 are open to participants now.

Browse Papilledema studies →

Open to participants now

3 of the 11 studies in Papilledema with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Papilledema studies recruiting now, 1 sets no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 20 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Papilledema with a site in United States, or all of them as a file.
02

Study summary

In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight.

The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.

Read the detailed description

Fasting (8-h) blood samples (7.5 mL SST and 5 mL EDTA tubes, 12.5 mL total per session) will be collected approximately 180 days and 45 days before flight, and return to Earth +0-2 days and 30 days after landing.

Blood samples will be analyzed for vitamin status and one-carbon biochemistry, as previously described. One blood sample (collected before flight) will be analyzed for approximately 511 SNPs matching the profile of testing from our ongoing research related to optic disc edema. Serum samples will be analyzed for biochemistry measures evaluating endothelial function, vitamin status, and oxidative damage.

Nutritional status assessment data, including inflight dietary intake and body mass data, completed for routine medical requirements will be requested for data sharing. Inflight medical exercise log data as well as available standard measures data will also be requested for data sharing. Medication use/Med Logs will also be requested for data sharing.

Vascular function VENDYS-II (Endothelix, Inc) will be used to assess reactive hyperaemia through changes in fingertip temperature. The test consists of an automated blood pressure measurement followed by cuff occlusion of the right arm for 2 to 5 min. During this time, the fingertip temperature in the right hand decreases because of the lack of circulation in the fingertip. After the cuff is released, blood flow resumes, causing a temperature rebound in the fingertip in a manner that is proportional to vascular reactivity.

Advanced Glycation End (AGE) Products Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader (Diagnoptics Technologies, Groningen, the Netherlands). The AGE reader illuminates a skin surface of approximately 4 cm2, guarded against surrounding light, with an excitation light source with wavelength between 300 and 429 nm. This method is based on the fluorescent properties of certain AGEs accumulated in dermal tissue.

OCT and OCT-A Optical coherence tomography (OCT) and OCT-angiography (OCT-A) scans will be acquired using the Spectralis OCT2 (Heidelberg Engineering) before, during, and after flight. The scan pattern includes 24 B-scans centered in a radial pattern over the optic nerve head, as well as a 3.5 mm circle scan surrounding the optic nerve head for assessment of retinal nerve fiber layer thickness and choroid thickness. For OCT-A, five consecutive volume scans will be obtained in these regions, each containing 216 A-scans. These images will be registered, and the consecutive B-scans will be used to calculate the decorrelation among the images to provide split-spectrum amplitude decorrelation angiography (SSADA) images. This decorrelation between consecutive B-scan images will be used to highlight locations where there is blood flow. The density of the perfused peripapillary vessels within the various layers of the retina will be calculated to create a flow density map.

03

Conditions studied

  • Optic Disc Edema
  • Endothelial Dysfunction

Browse trials for

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be astronauts selected for 6-12 month missions on the International Space Station

Exclusion criteria

Exclusion Criteria:

  • Subjects taking B-vitamin supplements
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Supplemented with B-Complex

    Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station

    Drug: Vitamin B-Complex Supplement

Interventions

  • DrugVitamin B-Complex Supplement

    Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin

06

What researchers measure

Primary outcomes

  1. Optic Disc Edema

    Measure change in total retinal thickness during and after flight compared to preflight using OCT

    Time frame: 6 months

Secondary outcomes

  1. Endothelial function

    Assess reactive hyperemia through changes in fingertip temperature

    Time frame: 6 months

  2. Advanced Glycation End Products (AGE)

    Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader

    Time frame: 6 months

  3. Serum folate status

    Vitamin status assessed from a fasting blood sample

    Time frame: 6 months

  4. Red Blood Cell folate status

    Vitamin status assessed from a fasting blood sample

    Time frame: 6 months

  5. Vitamin B6 status

    Vitamin status assessed from a fasting blood sample

    Time frame: 6 months

  6. Vitamin B12 status

    Vitamin status assessed from a fasting blood sample

    Time frame: 6 months

  7. Glucose

    Serum glucose from a fasting blood sample

    Time frame: 6 months

  8. Nitric oxide

    Serum nitric oxide from a fasting blood sample

    Time frame: 6 months

  9. tetrahydrobiopterin

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  10. Dihydrobiopterin

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  11. Oxidized glutathione

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  12. Total antioxidant capacity

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  13. Advanced glycation end products

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  14. Albumin

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  15. Glycated albumin

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  16. 3-nitrotyrosine

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  17. Formate

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  18. MMP-2

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  19. MMP-9

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  20. TIMP-1

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  21. TIMP-2

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  22. Heparan sulfate

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  23. Syndecan-1

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  24. Glypican

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  25. Hyaluronan

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

  26. Total lipid peroxides

    Serum biochemistry from a fasting blood sample

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zwart SR, Laurie SS, Chen JJ, Macias BR, Lee SMC, Stenger M, Grantham B, Carey K, Young M, Smith SM. Association of Genetics and B Vitamin Status With the Magnitude of Optic Disc Edema During 30-Day Strict Head-Down Tilt Bed Rest. JAMA Ophthalmol. 2019 Oct 1;137(10):1195-1200. doi: 10.1001/jamaophthalmol.2019.3124. PubMed 31415055 ↗
  • Zwart SR, Gibson CR, Gregory JF, Mader TH, Stover PJ, Zeisel SH, Smith SM. Astronaut ophthalmic syndrome. FASEB J. 2017 Sep;31(9):3746-3756. doi: 10.1096/fj.201700294. Epub 2017 May 25. PubMed 28546443 ↗
  • Smith SM, Zwart SR. Spaceflight-related ocular changes: the potential role of genetics, and the potential of B vitamins as a countermeasure. Curr Opin Clin Nutr Metab Care. 2018 Nov;21(6):481-488. doi: 10.1097/MCO.0000000000000510. PubMed 30169456 ↗
  • McGregor HR, Lee JK, Mulder ER, De Dios YE, Beltran NE, Kofman IS, Bloomberg JJ, Mulavara AP, Smith SM, Zwart SR, Seidler RD. Ophthalmic changes in a spaceflight analog are associated with brain functional reorganization. Hum Brain Mapp. 2021 Sep;42(13):4281-4297. doi: 10.1002/hbm.25546. Epub 2021 Jun 9. PubMed 34105833 ↗
  • Laurie SS, Vizzeri G, Taibbi G, Ferguson CR, Hu X, Lee SMC, Ploutz-Snyder R, Smith SM, Zwart SR, Stenger MB. Effects of short-term mild hypercapnia during head-down tilt on intracranial pressure and ocular structures in healthy human subjects. Physiol Rep. 2017 Jun;5(11):e13302. doi: 10.14814/phy2.13302. PubMed 28611153 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2022 (actual). Primary completion is estimated for Jul 2032, 119 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2027 → Jul 2032 and completion Sep 2032 → Sep 2035.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
May 9, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Jul 1, 2032was Jul 2027
CompletionEst.
Sep 30, 2035was Sep 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 1, 2027→Jul 1, 2032
Nov 12, 2026
Study completion
Sep 30, 2032→Sep 30, 2035
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jul 1, 2027→Jul 1, 2032
    Study completion Sep 30, 2032→Sep 30, 2035
    + 3 other changes: verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05366933
Lead sponsor
National Aeronautics and Space Administration (NASA)
Responsible party
Sara R. Zwart, PhD (Deputy Manager for Nutritional Biochemistry, The University of Texas Medical Branch, Galveston) — Principal investigator
First posted
May 9, 2022
Start date
Aug 1, 2022
Primary completion
Jul 1, 2032 (estimated)
Completion
Sep 30, 2035 (estimated)
Last update
Nov 12, 2026

Study contacts

Sara Zwart, PhD
Contact
sara.zwart-1@nasa.gov
2814833753
Eden Fields
Contact
eden.e.fields@nasa.gov
2814837864
Sara R Zwart, PhD
principal investigator · UTMB

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion